Frost & Sullivan Independent Equity Research

RedHill Biopharma announces positive top-line results from Phase III study of RHB-104 in Crohn’s Disease; remission rates at week-52 are low by market comparison; Redhill plans to raise additional capital to support future clinical development; target price remains at NIS 2.59

Company: RedHill Biopharma

Sector: Pharmaceuticals

Report type: Immediate Report

Published on: 31 July, 2018

View Fullscreen

Download full report

RedHill research articles:

Q2-2018 ·

RedHill announces top-line results from Phase III study of RHB-104 in Crohn’s Disease; cash balance improved with $25M (gross) raised at a discount; Top-line results for TALICIA® (RHB-105) – H. pylori infection expected by the end of 2018; target price reduced to NIS 2.23

Quarterly Report ·

RedHill Biopharma Ltd.: Q3 results did not meet expectations mainly with GI drug sales; financially, capital raising of $20.6M (NIS 1.94 per share) positions Redhill with sufficient funds until 2018.

All articles loaded

No more articles to load

INDEPENDENT EQUITY RESEARCH

Tel: +972(0)9.950.2888
Email: equity.research@frost.com

Contact us

Copyright © 2020 Frost & Sullivan. All Rights Reserved. Privacy Policy.

Accessibility by WAH